DEA Updates Rules for Pharmacy Prescription Transfers
Published Date: 7/23/2026
Notice
Summary
The DEA is updating rules for pharmacies that transfer electronic prescriptions for certain controlled medicines (Schedules III-V). Pharmacies must keep better records showing where prescriptions go, making it easier to track and safer for everyone. Comments on these changes are open until September 21, 2026, and the update aims to use more electronic tools without adding extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
New E‑prescription Transfer Recordkeeping
If you operate a pharmacy, you must update electronic prescription records when transferring controlled‑substance prescriptions between pharmacies for initial filling. Both the transferring and receiving pharmacy must record the other pharmacy’s name, address, and DEA registration number, the names of the transferring and receiving pharmacists, and the date of transfer. The DEA estimates 66,088 registrants will make about 12,900,000 transfer entries annually, at 3 minutes (0.05 hours) per record, totaling 645,000 annual burden hours; the agency reports a $0 direct annual cost burden but monetizes the labor at $97.38/hour for a total value of $62,810,100.
Improved Tracking, Safer Prescription Transfers
The rule requires more complete electronic transfer records to make it easier to track transfers of controlled‑substance prescriptions and to make transfers safer for everyone. The agency states the update aims to use more electronic tools without adding extra costs, and public comments are open until September 21, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-09160, Implementing PATRIOT Act Improvements: Contraband Cigarettes and Smokeless Tobacco
Starting June 8, 2026, new rules crack down harder on illegal cigarette and smokeless tobacco sales. The government lowered the amount that counts as smuggling from 60,000 to just 10,000 cigarettes and now includes smokeless tobacco in the crackdown. Sellers and distributors must keep better records and report more info, making it tougher to dodge the law and protect honest businesses.
2026-14836, Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Title-U.S. Official Order Forms for Schedules I and II Controlled Substances DEA Form 222
The DEA is keeping the current rules for ordering the most tightly controlled drugs using DEA Form 222, with no changes. This affects businesses and people who handle Schedule I and II substances, making sure the process stays smooth and secure. They’re asking for public feedback by September 21, 2026, but there’s no new cost or paperwork burden coming your way.
2026-14935, United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
The U.S. government says Edwards LifeSciences broke the rules when it bought JC Medical from Genesis MedTech. Edwards must pay $10 million, Genesis pays $2 million, and Edwards has to get approval before buying any company working on special heart valve devices in the U.S. This keeps the market fair and protects competition in heart health tech.
2026-14838, Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Previously Approved Collection; Title-Recordkeeping for Partial fills of Prescriptions
The DEA is updating how pharmacies and drug handlers keep records when prescriptions are only partly filled. This affects anyone who manages controlled substances and aims to make recordkeeping clearer and easier, with a chance to comment until September 21, 2026. The update won’t cost extra but will help keep drug tracking accurate and smooth.
Previous / Next Documents
Previous: 2026-14836, Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Title-U.S. Official Order Forms for Schedules I and II Controlled Substances DEA Form 222
The DEA is keeping the current rules for ordering the most tightly controlled drugs using DEA Form 222, with no changes. This affects businesses and people who handle Schedule I and II substances, making sure the process stays smooth and secure. They’re asking for public feedback by September 21, 2026, but there’s no new cost or paperwork burden coming your way.
Next: 2026-14838, Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Previously Approved Collection; Title-Recordkeeping for Partial fills of Prescriptions
The DEA is updating how pharmacies and drug handlers keep records when prescriptions are only partly filled. This affects anyone who manages controlled substances and aims to make recordkeeping clearer and easier, with a chance to comment until September 21, 2026. The update won’t cost extra but will help keep drug tracking accurate and smooth.